Zenas BioPharma, Inc. ZBIO
Set alert
27.57 USD -0.05 -0.18%
As of Nov 3, 9:32 AM ET
27.84 Day range 27.85
13.50 52-week range 44.60
- YTD
- -24.07%
- 1 year
- -12.00%
- Open
- 27.85
- Prev close
- 27.62
- Mkt cap
- 1.81B
- Vol
- 2.18K
- Avg vol
- 647.61K
- EPS
- -9.63
- P/E
- 0.00
- Div yield
- 0.00%
More statistics
- Low
- 27.84
- High
- 27.85
- Forward P/E
- -5.93
- Beta
- -0.86
- Short ratio
- 17.28
- Inst. own
- 105.72%
- Dividend
- 0.00
- Ex-div date
- Earnings
- Nov 18, 2026
- 50-d avg
- 29.48
- 200-d avg
- 24.95
- 1y target
- 47.88
Analyst view
Consensus: strong buy
Strong buy
Price target (mean) 47.88 +73.6% upside
Now 27.57
- Target (low)
- 32.00
- Target (mean)
- 47.88
- Target (high)
- 59.00
Ratings (0m) 8 7 buy · 1 hold · 0 sell
- Strong buy0
- Buy7
- Hold1
- Sell0
- Strong sell0
Recommendation trend
- This month 8
- 1 month ago 8
- 2 months ago 8
Earnings and revenue estimates
Consensus for the coming quarters and fiscal years
| Period | EPS estimate | Low – high | Year ago | EPS growth | Revenue estimate | Revenue growth | Analysts |
|---|---|---|---|---|---|---|---|
| Current quarter | -1.27 | -1.31 – -1.23 | -1.22 | -4.1% | 0 | 0.0% | 2 |
| Next quarter | -1.28 | -1.31 – -1.25 | -1.39 | +7.9% | 14.07M | 0.0% | 2 |
| Current year | -5.62 | -5.83 – -5.40 | -4.83 | -16.2% | 12.26M | +22.6% | 2 |
| Next year | -4.66 | -5.11 – -4.21 | -5.62 | +17.0% | 57.93M | +372.5% | 2 |
Upgrades and downgrades
The latest rating changes
| Date | Firm | Action | From | To |
|---|---|---|---|---|
| Oct 13, 2026 | HC Wainwright & Co. | Reiterated | Buy | Buy |
| Sep 30, 2026 | Citigroup | Maintained | Buy | Buy |
| Sep 30, 2026 | Wedbush | Reiterated | Outperform | Outperform |
| Sep 30, 2026 | HC Wainwright & Co. | Reiterated | Buy | Buy |
| Aug 14, 2026 | Morgan Stanley | Maintained | Equal-Weight | Equal-Weight |
| Aug 14, 2026 | Guggenheim | Reiterated | Buy | Buy |
| Aug 14, 2026 | Wedbush | Reiterated | Outperform | Outperform |
| May 15, 2026 | HC Wainwright & Co. | Reiterated | Buy | Buy |
| May 14, 2026 | Morgan Stanley | Maintained | Equal-Weight | Equal-Weight |
| Mar 17, 2026 | Citigroup | Maintained | Buy | Buy |
| Mar 17, 2026 | Guggenheim | Maintained | Buy | Buy |
| Mar 17, 2026 | Morgan Stanley | Maintained | Equal-Weight | Equal-Weight |
| Mar 17, 2026 | HC Wainwright & Co. | Reiterated | Buy | Buy |
| Feb 10, 2026 | HC Wainwright & Co. | Reiterated | Buy | Buy |
| Jan 6, 2026 | Morgan Stanley | Downgrade | Overweight | Equal-Weight |
| Dec 22, 2025 | Wedbush | Reiterated | Outperform | Outperform |
| Nov 26, 2025 | Evercore ISI Group | Initiated | — | Outperform |
| Nov 13, 2025 | Morgan Stanley | Maintained | Overweight | Overweight |
| Oct 28, 2025 | Citigroup | Maintained | Buy | Buy |
| Oct 28, 2025 | Morgan Stanley | Maintained | Overweight | Overweight |
| Oct 28, 2025 | HC Wainwright & Co. | Maintained | Buy | Buy |
| Oct 9, 2025 | Wedbush | Maintained | Outperform | Outperform |
| Oct 9, 2025 | HC Wainwright & Co. | Reiterated | Buy | Buy |
| May 16, 2025 | HC Wainwright & Co. | Reiterated | Buy | Buy |
| Mar 20, 2025 | Wedbush | Initiated | — | Outperform |
| Mar 12, 2025 | Guggenheim | Reiterated | Buy | Buy |
| Mar 12, 2025 | HC Wainwright & Co. | Reiterated | Buy | Buy |
| Feb 4, 2025 | Wolfe Research | Initiated | — | Outperform |
| Dec 16, 2024 | HC Wainwright & Co. | Initiated | — | Buy |
| Dec 11, 2024 | Morgan Stanley | Maintained | Overweight | Overweight |